Study details
Enrolling now
AlloNK® Trial
Artiva Biotherapeutics, Inc.
NCT IDNCT06991114ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
90
Study length
about 3.6 years
Ages
18+
Locations
16 sites in AL, AZ, CA +6
What this study is about
Researchers are testing the safety and effectiveness of AlloNK®, a non-genetically modified allogeneic NK cell therapy, combined with rituximab in people with relapsing forms of B-cell dependent rheumatologic diseases. The trial will last for about 1302 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Allogeneic NK Cells
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Safety
Body systems
Immune